New Launch28 Feb 2025, 02:20 pm
Biocon Limited launches GLP-1, Liraglutide, in the United Kingdom
AI Summary
Biocon Limited, an innovation-led global biopharmaceutical company, has announced the launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity, in the United Kingdom. The drug-device combination will be marketed under the brand names Liraglutide Biocon for diabetes (gVictoza®) and Biolide for chronic weight management (gSaxenda®). This launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., making Biocon Limited the first generics company to obtain approval for gliraglutide in a major regulated market.
Key Highlights
- Biocon Limited launches GLP-1, Liraglutide, in the United Kingdom
- Drug-device combination marketed under Liraglutide Biocon for diabetes and Biolide for chronic weight management
- First generics company to obtain approval for gliraglutide in a major regulated market
- Launch underpins Biocon’s scientific and manufacturing capabilities in developing and bringing to market complex, vertically integrated, GLP-1 formulations
- Biocon remains committed to reinforcing its position as a key player in GLP-1 therapies